Talk:Amifampridine

External links modified
Hello fellow Wikipedians,

I have just added archive links to 1 one external link on 3,4-Diaminopyridine. Please take a moment to review my edit. If necessary, add after the link to keep me from modifying it. Alternatively, you can add to keep me off the page altogether. I made the following changes:
 * Added archive https://web.archive.org/20150521162420/http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=464814 to http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=464814

When you have finished reviewing my changes, please set the checked parameter below to true to let others know.

Cheers.—cyberbot II  Talk to my owner :Online 14:41, 18 January 2016 (UTC)

Unsupported/Incorrect Information
These two sentences were moved to Talk as they are not supported by the references cited and appear to be incorrect. The first statement mistakes the a type of FDA citation ("483") with the number of citations. The second statement refers to a document which appears to endorse use of the free base for LEMS treatment despite the deficit of preclinical toxicology and pharmacology studies.


 * Other commentators noted, however, that Jacobus was not able to meet the needs of all people who could benefit from the drug via its free program, and that its manufacturing practices had quality control problems, with 483 FDA citations in 2011 and 2012. Similarly, at the urging of Assistance Publique-Hôpitaux de Paris, the French drug authority had reviewed the use of the free base in light of the manufactured phosphate form in 2006, and had urged doctors in France not to use the free base form due to quality issues.

Prithason (talk) 14:13, 10 May 2019 (UTC)